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Abstract 
Importance: Neuroimaging has recently been incorporated in the clinical diagnostic criteria 
for behavioral variant frontotemporal dementia (bvFTD). Although neuroimaging has a 
reasonable accuracy to differentiate bvFTD from other neurodegenerative disorders, its value 
for the differentiation of bvFTD among subjects with an acquired frontal lobe syndrome is 
unknown. 
Objective: to determine the diagnostic accuracy of MRI, additional [18F]FDG-PET, and their 
combination for bvFTD.  
Design: The late-onset frontal lobe syndrome (LOF) study is a prospective cohort study with 
a symptom based inclusion and 2 years of clinical, radiological and neuropsychological 
follow-up. Radiological reviewers were blinded to the clinical diagnosis. 
Setting: multi-center, memory clinics 
Participants: Participants were aged 45-75 years. Out of 137 patients included at baseline, a 
follow-up diagnosis was available in 116. At baseline 111 patients had a brain MRI scan and 
74 patients underwent additional [18F]FDG-PET. They were classified as having 
probable/definite bvFTD or a non-bvFTD diagnosis after 2 years of follow-up. 
Main Outcome and Measure: MRIs and [18F]FDG-PET scans were visually rated on frontal 
and/or anterior temporal changes at baseline, and were classified to be consistent with FTD 
or not. The follow-up diagnosis was used as the gold standard to calculate sensitivity and 
specificity for baseline neuroimaging.  
Results: 27 patients had probable/definite bvFTD and 84 patients had a non-bvFTD 
diagnosis (psychiatric diagnosis or other neurological disorders). MRI had a sensitivity of 70% 
(95% CI 52-85%) with a specificity of 93% (95% CI 86-97%). [18F]FDG-PET had a sensitivity 
of 90% (95% CI 66-100%) with a specificity of 68% (95% CI 56-79%). The sensitivity of 
combined neuroimaging was 96% (95% CI 85-100%) with a specificity of 73% (95% CI 63-
81%). In 75% of the genetic FTD cases, MRI lacked typical frontotemporal atrophy. 40% of 
cases with a false positive [18F]FDG-PET scan had a psychiatric diagnosis.  
Conclusions and Relevance: A good diagnostic accuracy was found for MRI and additional 
[18F]FDG-PET for bvFTD in a late-onset frontal lobe syndrome cohort. Caution with the 
interpretation of neuroimaging results should especially be taken in cases with a genetic 
                                                                                                               Vijverberg et al. 
 
5 
background and in cases with a psychiatric differential diagnosis where [18F]FDG-PET is the 
only abnormal investigation.  
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Introduction 
In clinical practice, behavioral variant frontotemporal dementia (bvFTD) has a broad and 
heterogeneous differential diagnosis including both neurodegenerative diseases and 
psychiatric disorders. Identifying the specific cause of a late-onset frontal lobe syndrome 
represents a major challenge1-3 and will be increasingly important when disease-specific 
treatments become available.  
 
As described in the international consensus criteria for bvFTD (FTDC), the presence of 
frontotemporal abnormalities on neuroimaging is considered as a biomarker for bvFTD, and is 
mandatory for the diagnosis probable bvFTD4. However, the diagnostic accuracy of magnetic 
resonance imaging (MRI) and ([18F]-fluorodeoxyglucose-positron emission tomography 
([18F]FDG-PET) for bvFTD varies across different studies 5-9. Generally, these studies have 
measured the diagnostic accuracy of frontotemporal changes on neuroimaging for bvFTD 
among cohorts of patients with neurodegenerative disorders. 
 
Several studies have reported changes in frontotemporal regions on MRI and [18F]FDG-PET-
scan in mood disorders and schizophrenia, psychiatric disorders that may also present with a 
frontal lobe syndrome10-14. This might affect the diagnostic accuracy of neuroimaging for 
bvFTD. In other words, the value of neuroimaging for the differentiation of bvFTD among 
subjects with an acquired frontal lobe syndrome is unknown. 
 
Therefore, the aim of this study was to measure the diagnostic accuracy of MRI and 
additional [18F]FDG-PET for bvFTD in a large and clinically relevant cohort, consisting of 
subjects with a late-onset frontal lobe syndrome15. 
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Methods 
Patients 
We selected patients of the Late Onset Frontal lobe (LOF) study, which is a multi-center 
observational and prospective follow-up study16. In the LOF study 137 patients were 
prospectively included with a presentation of behavioral changes consisting of apathy, 
disinhibition, and/or compulsive/stereotypical behavior emerging between 45 and 75 years of 
age. The patients had been referred to the VUMC Alzheimer Center and the Department of 
Old Age Psychiatry of the GGZInGeest, Amsterdam, the Netherlands, between April 2011 
and June 201317.  Patients were included in the study when behavioral complaints dominated 
the presentation and when they had a score of ≥ 11 on the Frontal Behavioural Inventory 
(FBI)18 or a score of ≥ 10 on the Stereotypy Rating Inventory (SRI)19. All patients underwent 
full neurological and psychiatric examination at baseline and at two-year-follow-up. Cognitive 
screening tests included the Mini Mental State Examination (MMSE)20 and the Frontal 
Assessment Battery (FAB)21. Additional information of the assessment is described in the 
LOF study design16. The local institutional review board approved this study and a written 
informed consent was obtained from all participants. 
 
Neuroimaging 
All patients underwent a brain MR (3T Signa HDxt whole-body MRI system GE Medical 
Systems Milwaukee, WI, USA) using an 8-channel head coil with foam padding to restrict 
head motion. Image acquisition included an established standard MRI protocol for memory 
clinic patients [17]. A sagittal 3D heavily T1-weighted gradient-echo sequence with coronal 
reformats, a sagittal 3D T2-weighted fluid-attenuated inversion-recovery (FLAIR) fast spin-
echo with axial reformats, a transverse T2-weighted fast spin-echo, a transverse T2* 
susceptibility sequence, and diffusion weighted imaging/EPI. All sequences were performed 
using 3mm slices/reformats with 1 mm in-plane resolution and provided whole brain 
coverage17. An experienced neuroradiologist (FB or MPW), unblinded for the study design but 
blinded to the patients’ symptoms and medical history, evaluated the images with respect to 
global cortical atrophy (GCA), medial temporal lobe atrophy (MTA), and white matter 
hyperintensities (Fazekas) according to established and validated visual rating scales22-24. In 
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addition, they classified the imaging findings based on frontal and/or anterior temporal 
atrophy on MRI tot be consistent with FTD or not.  
 
In case of normal MRI findings or doubt on the interpretation of the abnormalities being 
explanatory for the behavioral changes, an [18F]FDG-PET-scan was made. [18F]FDG-PET-
scans were made on an ECAT EXACT HR+ scanner (Siemens/CTI, Knoxville, USA). 185 
MBq [18F]FDG was injected after subjects rested for ten minutes with minimal noise and eyes 
closed in a dimly lit room. PET scans were acquired 45 minutes after injection during fifteen 
minutes (3 frames of 5 minutes). [18F]FDG-PET-scans were assessed visually and interpreted 
by an experienced nuclear medicine physician (BB) on frontal and/or anterior temporal 
hypometabolism based on the summed images of all the frames, unblinded for the study 
design and blinded to the patients’ symptoms, complaints and medical history.  
 
Diagnostic procedure 
A consensus diagnosis between the neurologist and the psychiatrist was made based upon 
the relevant clinical information and additional investigations, including results of CSF 
biomarkers, MRI and [18F]FDG-PET at baseline. All patients with a positive family history for 
early-onset dementia were referred for clinical genetic counseling. If deemed appropriate, 
genetic screening included the MAPT, GRN, PSEN1, and APP genes. In all subjects of whom 
DNA was available (n=137) C9orf repeat expansion was tested. After two years of follow-up, 
neuropsychiatric examination, neuropsychological examination and the brain MRI were 
repeated, followed by establishment of the final multidisciplinary diagnosis. Based on the 
follow-up diagnosis, patients were divided into two groups: having bvFTD (defined as 
probable and definite bvFTD) or not having bvFTD (non-bvFTD). All probable bvFTD patients 
at follow-up had neuroimaging consistent with FTD. Subsequently the sensitivity and 
specificity of the baseline MRI and additional [18F]FDG-PET were calculated, using the follow-
up diagnosis as the gold standard. From the original LOF cohort of 137 cases, a total of 26 
patients were excluded. Three patients were excluded from the final analysis with a two-year 
follow-up diagnosis of possible bvFTD, whereas three patients died without post mortem 
verification or a clear clinical diagnosis. Fifteen patients were lost to follow-up, whereby most 
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of these participants withdrew from the study. Five cases were excluded based on insufficient 
quality of their baseline MRI that had been performed elsewhere.   
 
Statistical analysis 
Data analysis was performed using IBM SPSS statistics version 20.0 (IBM SPSS Statistics, 
Armonk, NY). Independent samples t-test for continuous measures, Chi-square tests for 
categorical variables and Mann-Whitney U test for variables that are not normally distributed 
were performed to compare age, gender, duration of onset symptoms at presentation, 
education in years, MMSE, FAB, FBI and SRI between the 2 groups. MRI visual rating scores 
comparison was done with the Chi-square test for trend. Sensitivities and specificities for the 
MRI scans of the brain and [18F]FDG-PET-scans were calculated with cross tables with 95% 
confidence interval. The statistical significance was set to p-value <0.05.  
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Results 
Clinical and demographical characteristics 
The two-year-follow-up multidisciplinary diagnoses consisted of probable/definite bvFTD in 27 
patients (24%) and non-bvFTD in 84 patients. Of the 27 patients in probable/definite bvFTD 
group, 4 patients were diagnosed with definite bvFTD consisting of two C9orf72 
hexanucleotide repeat expansion, one progranulin mutation and a histopathological-
confirmed tauopathy. The non-bvFTD group consisted of patients diagnosed with other types 
of dementia (n=28, 25%), psychiatric disorders (n=44, 40%) and other neurological diseases 
(n=12, 11%). The most common neurodegenerative diagnoses were Alzheimer’s disease 
(n=7), vascular cognitive impairment (n=6), progressive supranuclear palsy (n=4) and 
dementia with Lewy bodies (n=4). The most common psychiatric diagnoses were major 
depression (n=11) and bipolar disorder (n=6). Other neurological disorders were Parkinson’s 
disease (n=2), multiple sclerosis (n=2), histopathologically-confirmed limbic encephalitis (n=1) 
and post-anoxic encephalopathy (n=1). Their clinical and demographical characteristics are 
shown in table 1. The patients with bvFTD diagnosis after two-year-follow-up were more often 
male and presented more often with stereotypical symptoms than the non-bvFTD group. 
 
Procedure neuroimaging 
The included 111 cases all underwent an MRI scan at baseline and 74 cases underwent 
additional [18F]FDG-PET-scan. Of the 74 cases with a additional [18F]FDG-PET-scan, nine 
cases had MRI scans with borderline abnormalities consistent with bvFTD, whereas 64 were 
considered as inconclusive (no abnormalities). Of the 37 patients without an [18F]FDG-PET-
scan, sixteen MRI scans showed abnormalities consistent with bvFTD, and in nineteen cases 
the MRI findings were inconclusive, however the patient refused or there were technical 
problems with the [18F]FDG-PET-scanner. In two patients the MRI scan showed findings 
suggestive of an alternative clinical diagnosis (Multiple sclerosis and vascular cognitive 
impairment (VCI)). 
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Neuroimaging for probable/definite bvFTD 
Of the 27 patients with a diagnosis of probable/definite bvFTD at two-year-follow-up, 19 
patients had MRI features consistent with bvFTD at baseline and ten patients revealed 
frontotemporal hypometabolism on the additional [18F]FDG-PET-scan at baseline. Of these 
ten patients, eight patients showed no clear abnormalities on MRI at baseline and these were 
considered as inconclusive. Two out of the 27 patients with probable/definite bvFTD at two-
year-follow-up had abnormalities consistent with bvFTD on MRI and on [18F]FDG-PET at 
baseline. The MRI visual ratings scores at baseline are described in table 2, showing a 
significantly higher MTA and GCA scores in bvFTD compared to the non-FTD group. Overall, 
predominant of changes on MRI and the additional [18F]FDG-PET on the right side of the 
brain were found and more often in the temporal lobe than in the frontal lobe. 
 
Sensitivity and specificity of MRI and additional [18F]FDG-PET-scan  
The sensitivity of frontotemporal atrophy on the baseline MRI for bvFTD was 70% (95% CI 
52-85%) and the specificity was 93% (95% CI 86-97%). This yielded positive and negative 
predictive values of 76% (95% CI 57-90%) and 91% (95% CI 84-96%). The sensitivity for the 
additional [18F]FDG-PET-scan at baseline was 90% (95% CI 66-100%) and the specificity 
68% (95% CI 56-79%). This yielded positive and negative predictive values of 33% (95% CI 
18-51%) and 98% (95% CI 90-100%). The sensitivity of combined neuroimaging in bvFTD, 
MRI and additional [18F]FDG-PET-scan together, was 96% (95% CI 85-100%) and the 
specificity was 73% (95% CI 63-81%). The positive and negative predictive values of 
neuroimaging in a frontal lobe syndrome cohort for bvFTD were 53% (95% CI 40-67%) and 
98% (95% CI 93-100%). 
 
False negative cases 
Eight patients showed no frontotemporal atrophy on the MRI at baseline, but were diagnosed 
with probable/definite bvFTD at two-year-follow-up. Among these patients, 3 patients were 
diagnosed with definite bvFTD; the first patient had a progranulin mutation with asymmetric 
atrophy in the right temporoparietal region on the MRI, reported as more consistent with AD. 
Another patient with a C9orf72 hexanucleotide repeat showed mild hippocampus atrophy only 
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on the left side (MTA grade 1) and no global atrophy (See figure 1C). The third patient with 
autopsy-based definite bvFTD, had generalized frontoparietal atrophy (GCA grade 1) and 
asymmetric atrophy of the temporal lobe right more than left, reported also more consistent 
with AD. In three patients (75%) with probable bvFTD, the neuroradiologist reported that the 
MRI was more consistent with another type of dementia (AD or VCI). For [18F]FDG-PET, one 
patient diagnosed with probable bvFTD had no hypometabolism on the [18F]FDG-PET-scan at 
baseline. 
 
False-positive cases 
Six patients of the non-FTD group demonstrated frontotemporal atrophy on the baseline MRI. 
These patients had bipolar disorder  (n=2), Parkinson’s disease (n=1), post-anoxic 
encephalopathy (n=1), semantic dementia (SD) (n=1) and behavioral changes due to 
relational problems. This group had predominantly low visual rating scores at baseline in the 
frontal and temporal regions; a description is shown in table 2. Twenty patients with frontal, 
anterior temporal or frontotemporal hypometabolism on the baseline [18F]FDG-PET-scan 
were diagnosed with a different disorder than probable/definite bvFTD. This group consisted 
of twelve patients with a psychiatric disorder; the most common alternative diagnosis was 
major depressive disorder (n=4) (MDD) (see figure 1A). These patients with psychiatric 
disorders had mainly decreased uptake in the frontal and temporal lobe, mostly bilaterally. 
Some patients also showed parietal hypometabolism mainly on the right side. Six patients 
were diagnosed with dementia other than bvFTD, including patients with Alzheimer disease 
(n=1), semantic dementia (SD) (n=3), progressive supranuclear palsy (PSP) (n=1) and 
cortical basal syndrome (CBS) (n=1). In this group the [18F]FDG-PET-scans showed mainly 
bilateral frontotemporal hypometabolism. Diagnoses at two-year-follow-up for patients with 
positive neuroimaging consistent with findings in bvFTD are presented in table 3. 
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Discussion 
We found a sensitivity of frontotemporal changes on MRI for bvFTD of 70% with a specificity 
of 93%. The additional [18F]FDG-PET, when the MRI was inconclusive, had a sensitivity of 
90% at the cost of a lower specificity of 68%. The combination of MRI and [18F]FDG-PET-
scan, had a sensitivity of 96% and a specificity of 73%. 
 
The current study found a moderate sensitivity for frontotemporal changes on MRI for bvFTD. 
This finding is predominately driven by the absence of structural abnormalities on baseline 
MRI in patients with probable bvFTD25. Moreover, 3 cases with a known pathogenic mutation 
had atypical findings on MRI. 26,27. In a previous study including post-mortem confirmed FTD 
cases, it was found that only 50% of the patients with FTD had abnormalities on the MRI at 
presentation6,8. One study among patients with a C9orf72 hexanucleotide repeat expansion 
reported a very low sensitivity of 13% for frontotemporal changes on MRI28. Our results seem 
to be more consistent with a sensitivity of 72% of MRI in a different cohort of patients carrying 
a C9orf72 hexanucleotide repeat expansion 29 and a sensitivity of 75% in clinically defined 
bvFTD 30. Overall, the sensitivity for MRI abnormalities varies and is moderate in different 
studies. Our findings suggest that the current clinical consensus criteria for bvFTD might be 
modified, and include the atrophy patterns described in known pathogenic mutations. 
Furthermore, the absence of atrophy on MRI in the early stage of bvFTD supports the search 
for specific biomarkers for bvFTD.  
 
In contrast, we found a high specificity of MRI for bvFTD, indicating that frontotemporal 
atrophy on MRI is suggestive of a neurodegenerative cause. Moreover, this result is 
consistent with the visual rating scores of global cortical atrophy and especially hippocampal 
atrophy in this study, which were significantly higher in the true-positive group and false-
negative group compared to the non-FTD group. In addition, the current findings also seem in 
line with previous studies that found higher MTA scores in FTD31-33. Taken together, MTA and 
GCA scores appear to be a good indicator for bvFTD in a late-onset frontal lobe syndrome. 
However, these visual rating scores are identical to patients with AD, and must be ruled out 
with additional investigations such as amyloid PET imaging34,35 or CSF biomarkers36. 
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Frontotemporal changes on [18F]FDG-PET had a high sensitivity for bvFTD, which is similar in 
previous studies5,37. An explaining for these results might by the early synaptic dysfunction in 
the frontal and temporal regions in FTD38, which is measured by [18F]FDG-PET39. In contrast, 
other studies found lower sensitivities for [18F]FDG-PET in patients with a C9orf72 
hexanucleotide repeat expansion28,29. This might be due to the atypical slow progression of 
this phenotype of bvFTD40. In addition, we found that a group of bvFTD patients without MRI 
changes had metabolism changes on the [18F]FDG-PET-scan. This finding is an argument for 
the suggestion that absence of sufficient atrophy could be an early stage of the disease. 
Therefore, [18F]FDG-PET seems a sensitive marker for early detection of bvFTD. 
 
However, in our clinically representative cohort of patients presenting with behavioral 
changes, we found that the specificity of [18F]FDG-PET was relatively low due to false positive 
scans in psychiatric cases and cases with various other types of dementia. Moreover, 40% of 
the false positively rated scans were of patients with psychiatric disorders.  This also may be 
explained by the synaptic dysfunction in psychiatric disorders in similar anatomic regions as 
FTD12,14,41-43. Our findings indicate that the interpretation of frontotemporal hypometabolism 
on [18F]FDG-PET should always be accompanied by a thorough clinical evaluation, such as a 
psychiatric and neurological examination. 
 
Another finding of the present study was the high sensitivity and a suboptimal specificity for 
the combination of MRI and additional [18F]FDG-PET-scan. The combined neuroimaging 
causes an increase in the diagnostic accuracy for bvFTD compared with the both individual 
imaging technics. Conclusively, these results support the notion of clinical practice to perform 
MRI investigation first in patients with a frontal lobe syndrome and clinically bvFTD, and if 
inconclusive for bvFTD, to perform a additional [18F]FDG-PET-scan. Moreover, coverage by 
Centers for Medicare en Medicaid Services (CMS) for [18F]FDG-PET for dementia requires 
diagnostic structural imaging first.  
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It could be discussed that in the present study SD (n=3), PSP (n=1) and CBS (n=1) patients 
were among the false positive rated scans on MRI and [18F]FDG-PET-scan, and this could 
indicate an incorrect evaluation of the images. However, this is not the case, since our study 
design asked the neuroradiologist for FTD specific abnormalities and not for the differentiation 
between bvFTD, SD, PSP or CBS. Moreover, these disorders are all part of the spectrum 
FTLD and share the same anatomical regions 44,45. Although, SD is associated with bilateral 
temporal changes, CBS with asymmetric changes and PSP with changes of the midbrain and 
frontal lobes, it is still difficult to differentiate between these disorders on neuroimaging46-48. 
From a clinical perspective, we might therefore have underestimated the specificity of MRI 
and [18F]FDG-PET-scan. Even when including these patients as FTD cases, specificity of MRI 
would not have surpassed 93% and for the [18F]FDG-PET-scan 74%. 
 
Considerable strengths of our study are the large and clinically well-phenotyped cohort and its 
study design. Patients were included based on their symptoms, thereby closely resembling 
daily practice in neuropsychiatric clinics. Another important strength is the blinding of the 
neuroimaging raters, although they were aware of the study design. Thus, we have attempted 
to avoid over-interpretation of the neuroimaging investigations. 
 
A limitation of this study is the rather limited number of cases with a definite FTD diagnosis 
based on autopsy and genetic testing. For the gold standard definition, we had to rely on the 
clinical consensus diagnosis and additional investigations at two-year-follow-up. Furthermore, 
it is important to bear in mind that there was a selection bias for the [18F]FDG-PET-scan, due 
to cases with a clear abnormal MRI who did not have [18F]FDG-PET. As a consequence, the 
sensitivity [18F]FDG-PET-scan may have been underestimated. Another source of uncertainty 
is the reliability of visual rating of the MRI and [18F]FDG-PET, in combination with the lacking 
data on interrater variability and interrater agreement of the assessment of the neuroimaging. 
This limits the accuracy of the present results to a certain degree and it gives a possible 
explanation of the finding that the correctly assessed scans in our study were with vast 
atrophy and high visual rating grades and the false positive scans showed less atrophy and 
lower visual rating grades.  
                                                                                                               Vijverberg et al. 
 
16 
 
Our study shows that atypical MRI atrophy patterns should not preclude genetic testing in 
case of suspected bvFTD. On the other hand, overinclusive bvFTD diagnosis of subjects with 
[18F]FDG-PET abnormalities in psychiatric disorders should be avoided by thorough 
psychiatric examination. Therefore, genetic testing and long-term follow-up, by a neurologist 
and psychiatrist, are of high relevance in the diagnosis of bvFTD. Nevertheless, the search 
for additional and disease specific biomarkers might further increase the diagnostic specificity 
of bvFTD. 
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Figures and tables 
Figure title and legend 
Figure 1. Four coronal T1 MRI slices and voxel-based [18F]FDG-PET images 
*Example of (A) Major Depression Disorder with true negative MR and false positive 
[18F]FDG-PET (B) Bipolar Disorder with false positive MR and [18F]FDG-PET (C) Definite 
bvFTD due to C9orf72 hexanucleotide repeat expansion with false negative MR and true 
positive [18F]FDG-PET (D) Probable bvFTD with true positive MR and [18F]FDG-PET. 
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Table 1. Clinical and demographical characteristics 
Characteristics FTD 
(n=27) 
Non-FTD (n = 
84) 
P-
Value 
Men, n (%) 16 (59) 68(81) 0.02a 
Age, mean (SD), y 62.9 (6.7) 61.2 (6.6) 0.23 
Duration of symptoms at presentation, mean 
(SD),y  
5.4(5.1) 3.7(3.9) 0.14 
Education, mean (SD), y 10.4(2.5) 10.2(2.6) (n=69) 0.69 
MMSE, mean (SD) 26.1(2.6) 26.4(2.7) 0.71 
FAB, mean (SD) 14.4(4.0) 14.9(2.9) 0.81 
FBI, mean (SD) 26.3(10.4) 24.1(9.5) 0.31 
SRI, mean (SD) 15.6.(10.8) 5.6(7.6) <0.001b 
 Abbreviations: FTD, frontotemporal dementia; FAB, Frontal Assessment Battery; FBI, Frontal 
Behavioral Inventory; MMSE, Mini-Mental State Examination; SRI, Stereotypy Rating 
Inventory. Significant at p<0.05. independent t-tests, unless otherwise stated. a: Chi-square 
test. b: Mann-Whitney test 
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Table 2. MRI Visual ratings scores at baseline. 
MRI Visual 
rating scores            
  FTD (n=27) Non-FTD (n=84)   
  
True positive 
(n=19) 
False 
negative 
(n=8) 
True negative 
(n=78) 
False 
positive (n=6) 
P-
value 
GCA, mean 
(SD) 1.16 (0.83) 0.88(0.35) 0.40(0.57) 0.83(0.75) 
<0.0
01 a 
Right, MTA, 
mean (SD)  2.42(1.54) 1.25(0.89) 0.58(0.73) 0.33(0.52) 
<0.0
01 a 
Left, MTA , 
mean (SD) 1.95(1.3) 0.88(0.64) 0.53(0.73) 0.17(0.41) 
<0.0
01 a 
Fazekas, mean 
(SD)  0.89(0.66) 0.500.76) 0.56(0.77) 0.50(0.84) 0.13 
 
Abbreviations: GCA, global cortical atrophy; MTA, medial temporal lobe atrophy. Chi-test. a 
Significant <0.001 FTD vs Non-FTD. 
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Table 3. Diagnoses of patients after two-year-follow-up with neuroimaging findings consistent 
with bvFTD pattern at baseline.  
MRI scans (N=25)   Frequency (n) 
      
True positive Probable bvFTD 18 
  Definite bvFTD (C9orf72) 1 
      
False positive Semantic Dementia 1 
  Post-anoxic-encephalopathy  1 
  Parkinson’s Disease Dementia 1 
  Bipolar Disorder 2 
  Relationship problems 1 
      
      
[18F]FDG-PET-scans (n=30)   Frequency (n) 
      
True positive Probable bvFTD 8 
  Definite bvFTD 2 
      
False positive Alzheimer’s  disease 1 
  Dementia others 5 
  Progressive Supranuclear Palsy 1 
  Corticobasal Degeneration 1 
  Semantic Dementia 3 
  Subjective cognitive decline 1 
  Vascular cognitive Impairment 1 
  Psychiatric disorders 12 
  Schizophrenia 1 
  Major depression 4 
  Bipolar Disorder 1 
  Personality disorder 1 
  Other psychiatric disorders 5 
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Figure 1. 
 
Fig. 1 Four coronal T1 MRI slices and voxel-based [18F]FDG-PET images (A) MDD with true 
negative MR and false positive [18F]FDG-PET (B) BD with false positive MR and [18F]FDG-
PET (C) Definite bvFTD due to C9orf72 hexanucleotide repeat with false negative MR and 
true positive [18F]FDG-PET (D) Probable bvFTD with true positive MR and [18F]FDG-PET.  
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